Yale scientists develop new cancer therapy
After 10 years of trial and error, Yale bioengineers have developed a new approach to brain-tumor chemotherapy that could potentially extend the life spans of countless cancer patients.
The therapy — developed by Mark Saltzman, chemical and bioengineering professor — involves adding polyethylene glycol, a water-soluble polymer known as PEG, to the anti-cancer drug camptothecin. Early trials performed on rats with brain tumors have shown that conjugation with PEG allows the drug to penetrate farther into the brain and remain effective longer.
The team published its results...
Sorry, but comments are disabled for this article.